Acute coronary syndrome (ACS) is a unifying term representing a common end result, acute myocardial ischemia. It encompasses acute myocardial infarction (MI) resulting in ST segment elevation MI (STEMI) or non STsegment elevation MI (NSTEMI) and unstable angina. 1 Currently, there are three main reperfusion strategies for STEMI: fibrinolytic therapy, primary percutaneous coronary intervention (PCI), and fibrinolytic-facilitated primary PCI. Approximately 95% of patients who are treated with primary PCI obtain complete reperfusion versus 50% to 60% of patients who are treated with fibrinolytics. 2 Several model of risk scores are developed for predicting short and mid-term outcomes in patients with ACS and to distinguish the patients at the highest risk or an adverse outcome who may benefit from aggressive therapies. The PURSUIT, TIMI, GRACE and FRISC risk score models are well validated in this regard. 3 Recently, the HEARTrisk score was developed. The Primary Angioplasty in Myocardial Infarction (PAMI) risk score is used to predict the six-month mortality. The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) risk score is used to predict the one-year mortality. 4 The development of both risk scores (PAMI and CADILLAC) was based on individuals treated by invasive procedures. The dynamic TIMI risk model is an upgrade of the classic TIMI risk score, using in-hospital events for an easy reassessment of the risk of Patients discharged from hospital. 4 The Thrombolysis In Myocardial Infarction (TIMI) risk score was developed as a bedside tool to stratify STEMI patients eligible for reperfusion by their mortality risk. 
Several model of risk scores are developed for predicting short and mid-term outcomes in patients with ACS and to distinguish the patients at the highest risk or an adverse outcome who may benefit from aggressive therapies. The PURSUIT, TIMI, GRACE and FRISC risk score models are well validated in this regard. 3 Recently, the HEARTrisk score was developed. The Primary Angioplasty in Myocardial Infarction (PAMI) risk score is used to predict the six-month mortality. The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) risk score is used to predict the one-year mortality. 4 The development of both risk scores (PAMI and CADILLAC) was based on individuals treated by invasive procedures. The dynamic TIMI risk model is an upgrade of the classic TIMI risk score, using in-hospital events for an easy reassessment of the risk of Patients discharged from hospital. 4 The Thrombolysis In Myocardial Infarction (TIMI) risk score was developed as a bedside tool to stratify STEMI patients eligible for reperfusion by their mortality risk. The TIMI risk score has shown to provide good discrimination in predicting mortality at 30 days and even up to 365 days. 5 Decision taken quickly and correctly in emergency room to distinguish which patients with STEMI could derive a benefit from invasive strategies using TIMI score. Also, TIMI risk score can be a good predictor to determine the extension of coronary artery disease in patients with STEMI. 6 Within the STEMI population, there is a spectrum of higher and lower risk patients. Stratification of risk in STEMI has been more difficult because primary PCI has been offered and incorporated into national and international guidelines to all patients without contraindication who present with clinical and electrocardiographic criteria. 7
Methods:
This study was an observational study conducted in the Department of cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh from April, 2015 to March, 2016. The study protocol was approved by the institutional review board of NICVD. All patients with ST segment elevation Myocardial Infarction undergoing primary percutaneous coronary intervention in NICVD during the specified period of time were the study population. A total of 64 consecutive patients were considered. Study subjects were divided in to two groups on the basis of TIMI risk score. In group I: patients with low TIMI risk score (0-4); in group II: Patients with high TIMI risk score (≥5). Patients with prior MI, patients with prior PCI, patients with prior CABG, patient with valvular heart diseases, patients with cardiomyopathy and patients with severe comorbidity were excluded from the study. Coronary artery disease severity was assessed by Vessels Score. In-hospital outcomes assessed were: a) Heart failure, b) Cardiogenic shock, c) Ventricular arrhythmia, d) Re-infarction, e) Stroke, and f) Death.
Analysis was performed with the statistical package SPSS 17. The continuous and discrete variables were expressed as mean and standard deviation (SD). Differences were analyzed with Student's t test to compare two variables. The categorical variables were expressed as frequencies and percentages and compared with chi-square or Fisher's exact test, Depending on the frequency of expected events. Differences were considered significant at a p value of less than 0.05.
Results:
A total of 64 patients with STEMI were enrolled in this study. 32 patients were taken with low TIMI risk (Group I) and 32 patients were taken with high TIMI risk (Group II). All the variables like baseline characteristics and outcome variables were compared between these two groups. The findings obtained from data analyses were documented below:
The age distribution of the patients in Table I shows that most of the study patients belonged to 46 -55 years age in both groups, which was 9 (28.1%) in low TIMI risk group and 14 (42.8%) with high TIMI risk group. The mean age was found 48.5±10.32years with low TIMI group and 52.65±10.54 years with high TIMI group. Analysis revealed statistically not significant mean age difference (p>0.05) between two groups by unpaired t-test. Table V shows the distribution of the study patients by in-hospital outcome.4(12.5%) patients developed heart failure in high TIMI group and no heart failure low TIMI group, cardiogenic shock 2(6.3%) in high TIMI group and 0(00%), ventricular arrhythmia 2(6.3%) in high TIMI group and 1(3.1%) in low TIMI group, reinfarction 1(3.1%) in high TIMI group and 1 (3.1%) in low TIMI group and death 1(3.1%) in high TIMI group and absent in low TIMI group. No stroke in both group. Heart failure and cardiogenic shock were significantly high in group II (p<0.01 and <0.05, respectively). Table VI shows the total adverse outcome was present 10(31.3%) in high TIMI group and 2(6.3%) in low TIMI group which was statistically significant (p=0.01). 
Discussion:
Male patient was predominant in the whole study population. Over all male and female ratios was 7.1. In another study in Bangladesh male 70(95%) and female 3(5%). 8 Female are less prone to developed IHD in premenopausal age due to protective role of estrogen, moreover smoking as a risk factor of IHD is less common in our country among female, which may explain male predominance of IHD. Female also have less access to medical facilities.
Table-III Comparison of the study population according to involvement of vessel (N=64).

Involvement of vessel
Group I (n = 32) Group II (n = 32) p-value In our study the most common complication was heart failure in high TIMI group followed by ventricular arrhythmia and cardiogenic shock. Reinfarction rate was 3.1% in both groups. Only one death (3.1%) was in high TIMI group, no stroke in any of the groups. Heart failure was found statistical significant difference (p=0.039) between the groups that was more in high TIMI group. One of the studies in abroad showed that Heart failure (15.3%), cardiogenic shock (10.9%) left ventricular arrhythmia (14.8%) in high TIMI group and in low TIMI group which were 4.1%, 1.5%, 5.9% and 2.1% respectively group. 10 Total hospital adverse outcome 12 (18.8%) of patients. Adverse outcome was present 10 (31.3%) in high TIMI group and 2 (6.3%) in low TIMI group. So, the study revealed that inhospital outcome was statistically significant (p=0.01). One study of Bangladesh showed 28.9% patients developed complications during the acute MI phase. 11
Conclusion:
In conclusion, this study found that high TIMI risk score was associated with more adverse in hospital outcome than patient of low TIMI risk score in patient with STEMI who underwent primary PCI. This study also demonstrated that the TIMI risk score carried a significant positive correlation with the coronary artery disease severity in patients with STEMI.
Study limitations
This study had some limitation which might affect the result i.e., this was a non-randomized study, number of study population was small, it was a single centered study, medium and long term outcomes of these patients were not included.
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